Loading...
XNAS
APTO
Market cap4mUSD
Apr 01, Last price  
1.71USD
Name

Aptose Biosciences Inc

Chart & Performance

D1W1MN
XNAS:APTO chart
No data to show
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
191.10%
Rev. gr., 5y
%
Revenues
0k
24,000100,02343,023168,807124,156000000000000000
Net income
-25m
L-50.34%
00005,052,5050000000-11,661,000-28,868,000-25,697,000-54,708,000-65,261,000-41,053,000-51,207,000-25,430,000
CFO
-36m
L-19.32%
000000000000-10,291,000-23,207,000-21,558,000-33,891,000-43,304,000-32,322,000-44,590,000-35,977,000
Earnings
Aug 06, 2025

Profile

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
URL
https://aptose.com/
IPO date
Jun 04, 1993
Employees
35
Domiciled in
CA
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
26,257
52,831
43,028
Unusual Expense (Income)
NOPBT
(26,257)
(52,831)
(43,028)
NOPBT Margin
Operating Taxes
(770)
Tax Rate
NOPAT
(26,257)
(52,831)
(42,258)
Net income
(25,430)
-50.34%
(51,207)
24.73%
(41,053)
-37.09%
Dividends
Dividend yield
Proceeds from repurchase of equity
23,433
6,881
101
BB yield
Debt
Debt current
428
394
301
Long-term debt
1,007
1,636
2,305
Deferred revenue
Other long-term liabilities
9,825
Net debt
(4,717)
(7,222)
(44,353)
Cash flow
Cash from operating activities
(35,977)
(44,590)
(32,322)
CAPEX
(5)
(29)
(24)
Cash from investing activities
18
9,960
30,066
Cash from financing activities
33,414
6,910
116
FCF
(28,740)
(49,437)
(42,978)
Balance
Cash
6,152
9,252
46,959
Long term investments
Excess cash
6,152
9,252
46,959
Stockholders' equity
(87,879)
(75,047)
(31,128)
Invested Capital
93,975
73,161
70,172
ROIC
ROCE
2,801.20%
EV
Common stock shares outstanding
698,980
6,755
6,151
Price
Market cap
EV
EBITDA
(25,853)
(52,365)
(42,500)
EV/EBITDA
Interest
207
770
Interest/NOPBT